stock-detail (PBYI)

Oncology Corporate Profile

Company Description

This company does not have any commercial products

This company does not have any pipeline products

Recent News Headlines

4/24/2017 12:18 pm

4/24/2017 12:18 pm

4/24/2017 12:18 pm

4/24/2017 12:18 pm

4/24/2017 12:18 pm

4/18/2017 12:19 pm

4/18/2017 12:19 pm

4/18/2017 12:19 pm

4/18/2017 12:19 pm

4/18/2017 12:19 pm

4/17/2017 06:18 am

4/17/2017 06:18 am

4/17/2017 06:18 am

4/17/2017 06:18 am

4/17/2017 06:18 am

Puma Biotechnology Presents Interim Results of Phase Ib/II FB-10 Trial of PB272 in Combination with Trastuzumab Emtansine (T-DM1) in HER2-Positive Metastatic Breast Cancer at the 2017 AACR Annual Meeting

4/2/2017 07:00 pm

[Business Wire] - Puma Biotechnology, Inc. , a biopharmaceutical company, announced that interim results from the Phase Ib/II FB-10 clinical trial of Puma’s investigational drug PB272 given in combination with the antibody drug conjugate T-DM1 were presented at the 2017 American Association for Cancer Research Annual Meeting that is currently taking place in Washington, D.C.

Puma Biotechnology Presents Results from the Phase II SUMMIT Trial of PB272 for ERBB2 (HER2) Mutant, HER2 Non-Amplified, Metastatic Cancer at the 2017 AACR Annual Meeting

4/2/2017 03:00 pm

[Business Wire] - Puma Biotechnology, Inc. , a biopharmaceutical company, announced that results from an ongoing Phase II clinical trial of Puma's investigational drug PB272 were presented at the 2017 American Association for Cancer Research Annual Meeting that is currently taking place in Washington, D.C.

Puma Biotechnology Launches Expanded Access Program for PB272 (Neratinib) for U.S. Patients with HER2-Positive Breast Cancer or HER2-Mutated Cancers

4/2/2017 02:03 pm

[Business Wire] - Puma Biotechnology, Inc. , a biopharmaceutical company, has initiated an expanded access program in the United States to provide its investigational therapy, PB272 , to patients with HER2-positive breast cancer or HER2-mutated cancers.